Past, present and future of hemophilia: A narrative review

Orphanet Journal of Rare Diseases

Volumn 7, Issue 1, 2012, Pages

  Franchini, Massimo ^a   Mannucci, Pier Mannuccio ^b  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

FIX; FVIII; Gene therapy; Plasma derived factor concentrates; Recombinant factor concentrates

Indexed keywords

ALPHA INTERFERON; ANTIRETROVIRUS AGENT; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8; DESMOPRESSIN; FRESH FROZEN PLASMA; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RIBAVIRIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTHROPATHY; BLEEDING; DRUG EFFICACY; DRUG SAFETY; EMERGENCY CARE; GENE TRANSFER; HEMOPHILIA; HEMOPHILIA A; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFESTYLE; QUALITY OF LIFE; REVIEW; VIRUS INACTIVATION;

EID: 84860348922     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-7-24     Document Type: Review

References (78)

1. The hemophiliac - from royal genes to gene therapy. Mannucci PM, Tuddenham EGD, N Engl J Med 2001 344 1773 1779 10.1056/NEJM200106073442307 11396445 (Pubitemid 32497033)
2. Hemophilias A and B. Bolton-Maggs PH, Pasi KJ, Lancet 2003 361 1801 1809 10.1016/S0140-6736(03)13405-8 12781551 (Pubitemid 36638432)
3. Hoyer LH, Hemophilia A, N Engl J Med 1994 330 38 47 10.1056/ NEJM199401063300108 8259143 (Pubitemid 24018616)
4. An account of an hemorrhagic disposition existing in certain families. Otto JC, Med Repos 1803 6 1 4
5. Genotype analysis identifies the cause of the "royal disease". Rogaev EI, Grigorenko AP, Faskhutdinova G, Kittler EL, Moliaka YK, Science 2009 326 817 10.1126/science.1180660 19815722
6. The history of haemophilia in the royal families of Europe. Stevens RF, Br J Haematol 1999 105 25 32 10366244
7. Christmas disease: a condition previously mistaken for haemophilia. Biggs R, Douglas AS, Macfarlane RG, Dacie JV, Pitney WR, Merskey C, O'Brien JR, Br Med J 1952 ii 1378 1382
8. Back to the future: a recent history of haemophilia treatment. Mannucci PM, Haemophilia 2008 14 Suppl. 3 10 18 18510516 (Pubitemid 351722377)
9. Hemophilia and related bleeding disorders: a story of dismay and success. Mannucci PM, Hematology Am Soc Hematol Educ Program 2002 1 1 9
10. Experience with prophylaxis in Sweden. Nilsson IM, Semin Hematol 1993 30 3 Suppl 2 16 19 8303306 (Pubitemid 23212311)
11. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first twenty years. Mannucci PM, Haemophilia 2000 6 Suppl 1 60 67 10982270 (Pubitemid 30468295)
12. Hemophilia: treatment options on the twenty-first century. Mannucci PM, J Thromb Haemost 2005 1 1349 1355
13. Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia. White GC, McMillan CW, Kingdon HS, Shoemaker CB, N Engl J Med 1989 320 166 170 10.1056/NEJM198901193200307 2492083 (Pubitemid 19033095)
14. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Llewelyn CA, Hewitt PE, Knight RS, et al. Lancet 2004 363 9407 417 421 10.1016/S0140-6736(04)15486-X 14962520 (Pubitemid 38210057)
15. Recombinant clotting factors. Pipe SW, Thromb Haemost 2008 99 840 850 18449413 (Pubitemid 351705300)
16. Recombinant factor VIII concentrates. Franchini M, Lippi G, Semin Thromb Hemost 2010 36 493 497 10.1055/s-0030-1255443 20632247
17. The management of hemophilia in elderly patients. Franchini M, Tagliaferri A, Mannucci PM, Clin Interv Aging 2007 2 361 368 18044186
18. Co-morbidities and quality of life in elderly persons with haemophilia. Franchini M, Mannucci PM, Br J Haematol 2010 148 522 533 10.1111/j.1365-2141. 2009.08005.x 19958358
19. Italian Association of Hemophilia Centers: Mortality and causes of death in Italian persons with haemophilia, 1990-2007. Tagliaferri A, Rivolta GF, Iorio A, Oliovecchio E, Mancuso ME, Morfini M, Rocino A, Mazzucconi MG, Franchini M, Haemophilia 2010 16 437 446 20148978
20. Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice. Franchini M, Mannucci PM, Br J Clin Pharmacol 2011 in press
21. Clinical issues in inhibitors. Astermark J, Santagostino E, Keith Hoots W, Haemophilia 2010 16 Suppl 5 54 60 20590857
22. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert SA, Waters J, Berntorp E, FENOC Study Group, Blood 2007 109 546 551 10.1182/blood-2006-04-017988 16990605 (Pubitemid 46105952)
23. Systematic review of efficacy of rFVIIa and aPCC treatment for hemophilia patients with inhibitors. Knight C, Danø AM, Kennedy-Martin T, Adv Ther 2009 26 68 88 10.1007/s12325-008-0135-6 19156372
24. Efficacy of recombinant activated factor VII vs. activated prothrombin complex concentrate for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta-regression. Treur MJ, McCracken F, Heeg B, Joshi AV, Botteman MF, De Charro F, Van Hout B, Haemophilia 2009 15 420 436 10.1111/j.1365-2516.2008.01956.x 19335751
25. Recombinant factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with hemopphilia and inhibitors. Iorio A, Matino D, DAmico R, Makris M, Cochrane Database Syst Rev 2010 8 D004449 20687076
26. Inhibitor development: patient-determined risk factors. Astermark J, Haemophilia 2009 5 263 265
27. Assessing risk factors: prevention of inhibitors in haemophilia. Chambost H, Haemophilia 2010 16 Suppl 2 10 15 20132333
28. Is the incidence and prevalence of inhibitor greater with recombinant products? Yes. Aledort LM, J Thromb Haemost 2004 2 861 862 10.1111/j.1538-7836. 2004.00731.x 15140115 (Pubitemid 40185728)
29. Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development. Ettingshausen CE, Kreuz W, Haemophilia 2006 12 suppl 6 102 106 17123402 (Pubitemid 44741510)
30. Inhibtor development in haemophilia A: the role of von Willebrand factor/factor VIII concentrates. Goudemand J, Haemophilia 2007 13 Suppl 5 47 51 18078397 (Pubitemid 350253404)
31. VWF-containing FVIII concentrates and inhibitors in hemophilia A: a critical literature review. Franchini M, Lippi G, Thromb Haemost 2010 104 931 940 10.1160/TH10-03-0151 20838738
32. FVIII-LFB and Recombinant FVIII study groups: Influence of the type of factor VIII concentrate on the incidence of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe haemophilia A. Goudemand J, Rothschild C, Demiguel V, Vinciguerrat C, Lambert T, Chambost H, Borel-Derlon A, Claeyssens S, Laurian Y, Calvez T, Blood 2006 107 46 51 10.1182/blood-2005-04-1371 16166584 (Pubitemid 43054971)
33. Paediatric Working Party of UKHCDO: Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Chalmers EA, Brown SA, Keeling D, Liesner R, Richards M, Stirling D, Thomas A, Vidler V, Williams MD, Young D, Haemophilia 2007 13 149 155 10.1111/j.1365-2516.2006. 01418.x 17286767 (Pubitemid 46237946)
34. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Gouw SC, van der Bom JG, Marijke Van Den Berg H, Blood 2007 109 4648 4654 10.1182/blood-2006-11- 056291 17289808 (Pubitemid 46827754)
35. Rate of inhibitor development in previously-untreated hemophilia a patients treated with plasma-derived or recombinant factor VIII concentrates, A systematic review. Iorio A, Halimeh S, Holzhauer S, Goldenberg N, Marchesini E, Marcucci M, Young G, Bidlingmaier C, Brandao LR, Ettingshausen CE, Gringeri A, Kenet G, Knöfler R, Kreuz W, Kurnik K, Manner D, Santagostino E, Mannucci PM, Nowak-Göttl U, J Thromb Haemost 2010 8 1256 1265 10.1111/j.1538-7836. 2010.03823.x 20345722
36. Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers). Mannucci PM, Gringeri A, Peyvandi F, Santagostino E, Haemophilia 2007 13 Suppl 5 65 68 18078400 (Pubitemid 350253407)
37. Current co-ordinated activities of the PEDNET (European Paediatric Network for Haemophilia Management). Donadel-Claeyssens S, Haemophilia 2006 12 124 127 10.1111/j.1365-2516.2006.01202.x 16476085
38. Relevance of early paediatric care for boys with severe haemophilia. Chambost H, Meunier S, Arch Pediatr 2006 13 1423 1430 10.1016/j.arcped.2006.06. 020 16928435 (Pubitemid 44602426)
39. In vitro reactivity of factor VIII inhibitors with von Willebrand factor in different commercial factor VIII concentrates. Tagariello G, Zanotto D, Radossi P, Sartori R, Belvini D, Salviato R, Am J Hematol 2007 82 460 462 10.1002/ajh.20863 17211843 (Pubitemid 46849320)
40. Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation. Salvagno GL, Astermark J, Ekman M, Franchini M, Guidi GC, Lippi G, Poli G, Berntorp E, Haemophilia 2007 13 51 56 10.1111/j.1365-2516.2006.01400.x 17212725 (Pubitemid 46002345)
41. Von Willebrand factor: what is its role in the immune response in haemophilia? Kaveri S, Mannucci PM, Kurth MH, Ewing N, Kessler CM, Nugent DJ, Gomperts ED, Haemophilia 2010 Epub ahead of print
42. Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better. Mannucci PM, Blood Transfus 2010 8 288 291 20967171
43. Venous access in haemophilic children: choice and management. Santagostino E, Mancuso ME, Haemophilia 2010 16 Suppl 1 20 24 20059565
44. Arteriovenous fistula as stable venous access in children with severe haemophilia. Mancuso ME, Berardinelli L, Haemophilia 2010 16 Suppl 1 25 28 20536983
45. Long-term safety and feasibility of arteriovenous fistulae as vascular accesses in children with haemophilia: a prospective study. Santagostino E, Gringeri A, Berardinelli L, Beretta C, Muc,a-Perja M, Mannucci PM, Br J Haematol 2003 123 502 506 10.1046/j.1365-2141.2003.04632.x 14617014 (Pubitemid 37363495)
46. Improved treatment feasibility in children with hemophilia using arteriovenous fistulae: the results after seven years of follow-up. Mancuso ME, Berardinelli L, Beretta C, Raiteri M, Pozzoli E, Santagostino E, Haematologica 2009 94 687 692 10.3324/haematol.2008.001594 19286881
47. Arteriovenous fistola for long-term venous access for boys with hemophilia. McCarthy WJ, Valentino LA, Bonilla AS, Goncharova I, Taylor A, Pooley TA, Jacobs CE, J Vasc Surg 2007 45 986 990 10.1016/j.jvs.2006.12.060 17376644 (Pubitemid 46634917)
48. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, Ingram JD, Manco-Johnson ML, Funk S, Jacobson L, Valentino LA, Hoots WK, Buchanan GR, DiMichele D, Recht M, Brown D, Leissinger C, Bleak S, Cohen A, Mathew P, Matsunaga A, Medeiros D, Nugent D, Thomas GA, Thompson AA, McRedmond K, Soucie JM, Austin H, Evatt BL, N Engl J Med 2007 357 535 544 10.1056/NEJMoa067659 17687129 (Pubitemid 47236278)
49. Secondary prophylaxis therapy: what are benefits, limitations and unknown? Valentino LA, Haemophilia 2004 10 147 157 14962203 (Pubitemid 38312641)
50. Awaiting evidence-based recommendations on prophylaxis in adult patients. Tagliaferri A, Haemophilia 2010 16 955 956 10.1111/j.1365-2516.2010.02340.x 20579114
51. Controversies regarding the prophylactic management of adults with severe haemophilia A. Valentino LA, Haemophilia 2009 15 Suppl 2 5 18 20041959
52. The management of cardiovascular diseases in patients with hemophilia. Coppola A, Tagliaferri A, Franchini M, Semin Thromb Hemost 2010 36 91 102 10.1055/s-0030-1248728 20391300
53. Cardiovascular disease in haemophilia patients: a contemporary issue. Mannucci PM, Mauser-Bunschoten EP, Haemophilia 2010 16 Suppl 3 58 66 20586804
54. How I treat age-related morbidities in elderly persons with hemophilia. Mannucci PM, Schutgens RE, Santagostino E, Mauser-Bunschoten EP, Blood 2009 114 5256 5263 10.1182/blood-2009-07-215665 19837978
55. Hemophilia and cancer: a new challenge for hemophilia centers. Franchini M, Lippi G, Montagnana M, Targher G, Zaffanello M, Salvagno GL, Rivolta GF, Perna CD, Tagliaferri A, Cancer Treat Rev 2009 35 374 377 10.1016/j.ctrv.2009. 01.001 19195788
56. Challenges and controversies in haemophilia care in adulthood. Dolan G, Hermans C, Klamroth R, Madhok R, Schutgens RE, Spengler U, Haemophilia 2009 15 Suppl 1 20 27 19125937
57. Emerging clinical concerns in the ageing haemophilia patient. Konkle BA, Kessler C, Aledort L, Andersen J, Fogarty P, Kouides P, Quon D, Ragni M, Zakarija A, Ewenstein B, Haemophilia 2009 15 1197 1209 10.1111/j.1365-2516.2009. 02066.x 19686466
58. The treatment of hemophilia: from protein replacememt to AAV-mediated gene therapy. Youjin S, Jun Y, Biotechnol Lett 2009 31 321 328 10.1007/s10529-008-9869-0 18979215
59. Gene therapy: promises and problems. Pfeifer A, Verma IM, Annu Rev Genomics Hum Genet 2001 2 177 211 10.1146/annurev.genom.2.1.177 11701648 (Pubitemid 35265005)
60. Gene therapy: reality or myth for the global bleeding disorders community? Kelley K, Verma I, Pierce GF, Haemophilia 2002 8 261 267 10.1046/j.1365-2516.2002.00646.x 12010421 (Pubitemid 35277145)
61. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A, Glader B, Chew AJ, Tai SJ, Herzog RW, Arruda V, Johnson F, Scallan C, Skarsgard E, Flake AW, High KA, Nat Genet 2000 24 257 261 10.1038/73464 10700178 (Pubitemid 30132193)
62. Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. Powell JS, Ragni MV, White GC, Lusher JM, Hillman-Wiseman C, Moon TE, Cole V, Ramanathan-Girish S, Roehl H, Sajjadi N, Jolly DJ, Hurst D, Blood 2003 102 2038 2045 10.1182/blood-2003-01-0167 12763932 (Pubitemid 37122377)
63. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. Roth DA, Tawa NE, O-Brien JM, Treco DA, Selden RF, N Engl J Med 2001 344 1735 1742 10.1056/NEJM200106073442301 11396439 (Pubitemid 32497027)
64. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, Ozelo MC, Hoots K, Blatt P, Konkle B, Dake M, Kaye R, Razavi M, Zajko A, Zehnder J, Rustagi PK, Nakai H, Chew A, Leonard D, Wright JF, Lessard RR, Sommer JM, Tigges M, Sabatino D, Luk A, Jiang H, Mingozzi F, Couto L, Ertl HC, High KA, Kay MA, Nat Med 2006 12 342 347 10.1038/nm1358 16474400 (Pubitemid 43355084)
65. Update on progress and hurdles in novel genetic therapies for hemophilia. High KA, Hematology Am Soc Hematol Educ Program 2007 466 472
66. Factor VIII ectopically expressed in platelets: efficacy in hemophilia A treatment. Yarovoi HV, Kufrin D, Eslin DE, Thornton MA, Haberichter SL, Shi Q, Zhu H, Camire R, Fakharzadeh SS, Kowalska MA, Wilcox DA, Sachais BS, Montgomery RR, Poncz M, Blood 2003 102 4006 4013 10.1182/blood-2003-05-1519 12881300 (Pubitemid 37486982)
67. Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies. Shi Q, Wilcox DA, Fahs SA, Weiler H, Wells CW, Cooley BC, Desai D, Morateck PA, Gorski J, Montgomery RR, J Clin Invest 2006 116 1974 1982 10.1172/JCI28416 16823491 (Pubitemid 44033321)
68. The future of recombinant coagulation factors. Saenko EL, Ananyeva NM, Shima M, Hauser CA, Pipe SW, J Thromb Haemost 2003 1 922 930 10.1046/j.1538-7836.2003.00196.x 12871357
69. Special lectures in hemophilia management. Batorova A, High KA, Gringeri A, Haemophilia 2010 16 Suppl. 5 22 28 20590852
70. Strategies towards a longer acting factor VIII. Saenko EL, Pipe SW, Haemophilia 2006 12 42 51 10.1111/j.1365-2516.2006.01260.x 16683996
71. Longer-acting factor VIII to overcome limitations in haemophilia management: the PEGylated liposomes formulation issue. Di Minno G, Cerbone AM, Coppola A, Cimino E, Di Capua M, Pamparana F, Tufano A, Di Minno MN, Haemophilia 2010 16 Suppl 1 2 6 20536980
72. Prolonged bleeding free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes. Spira J, Plyusch OP, Andreeva TA, Andreev Y, Blood 2006 108 3668 3673 10.1182/blood-2006-03- 008276 16888098 (Pubitemid 44864543)
73. Effect of glycoPEGylation on factor VIIa binding and internationalization. Sen P, Ghosh S, Ezban M, Pendurthi UR, Vijaya Mohan Rao L, Haemophilia 2010 16 339 348 10.1111/j.1365-2516.2009.02121.x 19845776
74. Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII-an open label, exploratory, cross-over, phase I/II study. Spira J, Plyushch O, Zozulya N, Yatuv R, Dayan I, Bleicher A, Robinson M, Baru M, Haemophilia 2010 16 910 918 10.1111/j.1365-2516.2010.02273.x 20491957
75. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. Metzner HJ, Weimer T, Kronthaler U, Lang W, Schulte S, Thromb Haemost 2009 102 634 644 19806248
76. Prolonged in-vivo half-life of FVIIa by fusion to albumin. Schulte S, Weimer T, Wormsbaeche W, Kronthaler U, Groener A, Lang W, Liebing U, Blood 2007 110 924a abstract
77. A phase II open-label study evaluating hemostatic activity, pharmacokinetics and safety of recombinant porcine factor VIII (OBI-1) in hemophilia A patients with alloantibody inhibitors directed against human FVIII. Mahlangu J, Andreeva TA, Macfarlane D, Reding MT, Walsh C, Ritchie B, Ewing N, Kessler CM, Kempton C, Libby E, Zozulya N, Shapiro AD, St-Louis J, Warrier I, Keith Hoots W, Gruppo RA, Mueksch JN, Blood 2007 110 241a abstract
78. Uncertain times for research on hemophilia and allied disorders. Mannucci PM, Roberts HR, J Thromb Haemost 2005 3 423 10.1111/j.1538-7836.2005.01258.x 15748225 (Pubitemid 41632861)